Research programme: superoxide dismutase mimetic - PledPharma

Drug Profile

Research programme: superoxide dismutase mimetic - PledPharma

Alternative Names: Aladote; Aladote™; PP-100; PP-100-01A

Latest Information Update: 03 Mar 2016

Price : $50

At a glance

  • Originator PledPharma
  • Class Acetates; Antidotes; Ethylenediamines; Pyridines; Small molecules
  • Mechanism of Action Antioxidants; Iron chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Liver failure

Most Recent Events

  • 29 Feb 2016 PledPharm receives patent for PLED compounds for their anti-cancer effect by the European Patent Office
  • 29 Feb 2016 PledPharm receives use patent for PLED compounds by authorities in Canada, Russia, Mexico, Japan and Australia
  • 22 Sep 2015 PledPharma receives patent allowance for Aladote® in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top